PARP1 and breast carcinoma: Regarding breast cancer, a phase I CT suggested that PARP inhibition with olaparib concurrently with radiotherapy for early-stage, high-risk triple-negative breast cancer is well tolerated with no late treatment-related grade 3 or greater toxic adverse events.